Evidence map›Paper›PMID 25663943›Full record

ArticleJournal of Cancer2015

The prognostic value of irradiated lung volumes on the prediction of intra-/ post-operative mortality in patients after neoadjuvant radiochemotherapy for esophageal cancer. A retrospective multicenter study.

Philipp Günther Kup, Carsten Nieder, Hans Geinitz, Christoph Henkenberens, Angela Besserer, Markus Oechsner, Sabine Schill, Ralph Mücke, Vera Scherer, Stephanie E Combs and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Philipp Günther Kup1. Department of Radiation Oncology, Marien Hospital Herne, Clinic of Ruhr-Universität Bochum, Herne, Germany.
Carsten Nieder2. Department of Oncology and Palliative Medicine, Nordland Hospital Bodø, Norway.
Hans Geinitz3. Department of Radiation Oncology, Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria. ; 4. Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Christoph Henkenberens5. Department of Radiation Oncology, Medizinische Hochschule Hannover, Hannover, Germany.
Angela Besserer6. Department of Radiation Oncology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
Markus Oechsner4. Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Sabine Schill4. Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Ralph Mücke1. Department of Radiation Oncology, Marien Hospital Herne, Clinic of Ruhr-Universität Bochum, Herne, Germany. ; 7. Department of Radiation Oncology, Lippe Hospital, Lemgo, Germany.
Vera Scherer4. Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Stephanie E Combs4. Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Irenäus A Adamietz1. Department of Radiation Oncology, Marien Hospital Herne, Clinic of Ruhr-Universität Bochum, Herne, Germany. ; 8. Department of Radiation Oncology, Sankt Josef Hospital Bochum, Clinic of Ruhr-University Bochum, Bochum, Germany.
Khashayar Fakhrian1. Department of Radiation Oncology, Marien Hospital Herne, Clinic of Ruhr-Universität Bochum, Herne, Germany. ; 4. Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany ; 8. Department of Radiation Oncology, Sankt Josef Hospital Bochum, Clinic of Ruhr-University Bochum, Bochum, Germany.
Technical University of Munich · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the association between dosimetric factors of the lung and incidence of intra- and postoperative mortality among esophageal cancer (EC) patients treated with neoadjuvant radiochemotherapy (N-RCT) followed by surgery (S). METHODS AND MATERIALS: Inclusion criteria were: age < 85 years, no distant metastases at the time of diagnosis, no induction chemotherapy, conformal radiotherapy, total dose ≤ 50.4 Gy, and available dose volume histogram (DVH) data. One-hundred thirty-five patients met our inclusion criteria. Median age was 62 years. N-RCT consisted of 36 - 50.4 Gy (median 45 Gy), 1.8 - 2 Gy per fraction. Concomitant chemotherapy consisted of 5-Fluoruracil (5-FU) and cisplatin in 113 patients and cisplatin and taxan-derivates in 15 patients. Seven patients received a single cytotoxic agent. In 130 patients an abdominothoracal and in 5 patients a transhiatal resection was performed. The following dosimetric parameters were generated from the total lung DVH: mean dose, V5, V10, V15, V20, V30, V40, V45 and V50. The primary endpoint was the rate of intra- and postoperative mortality (from the start of N-RCT to 60 days after surgical resection).

resultsA total of ten postoperative deaths (7%) were observed: 3 within 30 days (2%) and 7 between 30 and 60 days after surgical intervention (5%); no patient died during the operation. In the univariate analysis, weight loss (≥10% in 6 months prior to diagnosis, risk ratio: 1.60, 95%CI: 0.856-2.992, p=0.043), Eastern Cooperative Oncology Group-performance status (ECOG 2 vs. 1, risk ratio: 1.931, 95%CI: 0.898-4.150, p=0.018) and postoperative pulmonary plus non-pulmonary complications (risk ratio: 2.533, 95%CI: 0.978-6.563, p=0.004) were significantly associated with postoperative mortality. There was no significant association between postoperative mortality and irradiated lung volumes. Lung V45 was the only variable which was significantly associated with higher incidence of postoperative pulmonary plus non-pulmonary complications (Exp(B): 1.285, 95%CI 1.029-1.606, p=0.027), but not with the postoperative pulmonary complications (Exp(B): 1.249, 95%CI 0.999-1.561, p=0.051).

conclusionsIrradiated lung volumes did not show relevant associations with intra- and postoperative mortality of patients treated with moderate dose (36 - 50.4 Gy) conventionally fractionated conformal radiotherapy combined with widely used radiosensitizers. Postoperative mortality was significantly associated with greater weight loss, poor performance status and development of postoperative complications, but not with treatment-related factors. Limiting the volume of lung receiving higher radiation doses appears prudent because of the observed association with risk of postoperative complications.

Indexed as

Dose-volume histogramEsophageal cancerLung toxicityNeoadjuvant radiochemotherapyPostoperative mortality

Identifiers

PMID25663943
PMCPMC4317761
OpenAlexW2129109234

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.